GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover

By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) – GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)